<?xml version="1.0"?> 
<rss version="2.0">

	<channel>
		<title>Novelstem International Corp. (NSTM) research, news, and more from GeoInvesting</title>
		<description>The latest research, news, and more from GeoInvesting for Novelstem International Corp. (NSTM)</description>
		<link>/companies/nstm_novelstem_international_corp_/overview</link>
		<language>en-us</language>
		<pubDate>Thu, 16 Apr 2026 02:52:23 GMT</pubDate>
		<lastBuildDate>Thu, 16 Apr 2026 02:52:23 GMT</lastBuildDate>
        <ttl>120</ttl>
        
        <item><title>Company description</title><guid isPermaLink="false">61187</guid><pubDate>Fri, 18 Dec 2020 20:33:08 GMT</pubDate><description>NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients&apos; resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.</description><link>/companies/nstm_novelstem_international_corp_/overview</link></item>
            
	
	</channel>  
	
</rss>
